Drug resistance in cancer: principles of emergence and prevention.

Although targeted therapy is yielding promising results in the treatment of specific cancers, drug resistance poses a problem. We develop a mathematical framework that can be used to study the principles underlying the emergence and prevention of resistance in cancers treated with targeted small-molecule drugs. We consider a stochastic dynamical system based on measurable parameters, such as the turnover rate of tumor cells and the rate at which resistant mutants are generated. We find that resistance arises mainly before the start of treatment and, for cancers with high turnover rates, combination therapy is less likely to yield an advantage over single-drug therapy. We apply the mathematical framework to chronic myeloid leukemia. Early-stage chronic myeloid leukemia was the first case to be treated successfully with a targeted drug, imatinib (Novartis, Basel). This drug specifically inhibits the BCR-ABL oncogene, which is required for progression. Although drug resistance prevents successful treatment at later stages of the disease, our calculations suggest that, within the model assumptions, a combination of three targeted drugs with different specificities might overcome the problem of resistance.

[1]  M. Clarke,et al.  Self-renewal and solid tumor stem cells , 2004, Oncogene.

[2]  D. Ho,et al.  HIV-1 dynamics in vivo: implications for therapy , 2003, Nature Reviews Microbiology.

[3]  B. Druker,et al.  Recent advancements in the treatment of chronic myelogenous leukemia. , 2002, Annual review of medicine.

[4]  W. Bornmann,et al.  A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. , 2005, Blood.

[5]  L. Loeb,et al.  Cancer cells exhibit a mutator phenotype. , 1998, Advances in cancer research.

[6]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[7]  H. Skipper,et al.  Establishment of cross-resistance profiles for new agents. , 1983, Cancer treatment reports.

[8]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[9]  M. Bronchud.  Principles of Molecular Oncology , 2000, Humana Press.

[10]  J H Goldie,et al.  A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.

[11]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[12]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[13]  F. Schabel,et al.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. , 1979, Cancer treatment reports.

[14]  T. Fojo,et al.  Strategies for reversing drug resistance , 2003, Oncogene.

[15]  G. Daley,et al.  Mechanisms and implications of imatinib resistance mutations in BCR-ABL , 2004, Current opinion in hematology.

[16]  L. Loeb,et al.  Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.

[17]  M A Nowak,et al.  Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.

[18]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Melo,et al.  Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. , 2001, Blood.

[20]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Hartwell,et al.  Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. , 2000, Cancer research.

[22]  M. Blagosklonny,et al.  Antiangiogenic therapy and tumor progression. , 2004, Cancer cell.

[23]  K. Shannon.  Resistance in the land of molecular cancer therapeutics. , 2002, Cancer cell.

[24]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[25]  Rocco Piazza,et al.  Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.

[26]  G. Kruh.  Introduction to resistance to anticancer agents , 2003, Oncogene.

[27]  C. Sawyers,et al.  Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Bronchud,et al.  Principles of Molecular Oncology , 2000, Humana Press.

[29]  T. Skorski,et al.  BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. , 2004, Blood.

[30]  B H Margolin,et al.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  John K Smith,et al.  Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. , 2004, Oncology research.

[32]  J. Folkman,et al.  Angiogenesis Inhibitors: A New Class of Drugs , 2003, Cancer biology & therapy.

[33]  Alan S. Perelson,et al.  Quantification of Cell Turnover Kinetics Using 5-Bromo-2′-deoxyuridine1 , 2000, The Journal of Immunology.

[34]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[35]  Ivan Damjanov,et al.  The Biological Basis of Cancer: Glossary , 2006 .

[36]  M. Blagosklonny.  STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’ , 2002, Leukemia.

[37]  F. McCormick.  New-age drug meets resistance , 2001, Nature.

[38]  B. Calabretta,et al.  The biology of CML blast crisis. , 2004, Blood.

[39]  J. Melo,et al.  Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease , 2004, International journal of hematology.